Beta Bionics, Inc. (BBNX)
Automate Your Wheel Strategy on BBNX
With Tiblio's Option Bot, you can configure your own wheel strategy including BBNX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BBNX
- Rev/Share 2.0298
- Book/Share 6.7553
- PB 2.1405
- Debt/Equity 0.0261
- CurrentRatio 10.636
- ROIC -0.2237
- MktCap 636596164.0
- FreeCF/Share -1.3873
- PFCF -10.5167
- PE -8.1055
- Debt/Assets 0.0233
- DivYield 0
- ROE -0.3157
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 2
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | BBNX | TD Cowen | -- | Hold | -- | $17 | Jan. 27, 2026 |
| Downgrade | BBNX | BofA Securities | Buy | Neutral | -- | -- | Jan. 9, 2026 |
| Resumed | BBNX | Stifel | -- | Buy | -- | $26 | Oct. 21, 2025 |
| Upgrade | BBNX | Goldman | Neutral | Buy | -- | $26 | Oct. 1, 2025 |
| Initiation | BBNX | Truist | -- | Buy | -- | $26 | June 16, 2025 |
| Initiation | BBNX | Lake Street | -- | Buy | -- | $30 | June 12, 2025 |
| Initiation | BBNX | Wolfe Research | -- | Outperform | -- | $20 | May 30, 2025 |
| Initiation | BBNX | Goldman | -- | Neutral | -- | $16 | May 30, 2025 |
| Initiation | BBNX | Leerink Partners | -- | Outperform | -- | $28 | Feb. 24, 2025 |
| Initiation | BBNX | Lake Street | -- | Buy | -- | $30 | Feb. 24, 2025 |
News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Beta Bionics, Inc. - BBNX
Published: February 03, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Beta Bionics, Inc. - BBNX
Published: January 27, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
SHAREHOLDER INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics
Published: January 27, 2026 by: Newsfile Corp
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their Options If you suffered significant losses in Beta Bionics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - January 27, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Aquestive Therapeutics, Inc. ("Beta Bionics" or the …
Read More
INVESTOR ALERT: Investigation of Beta Bionics, Inc. (BBNX) by Holzer & Holzer, LLC
Published: January 26, 2026 by: GlobeNewsWire
Sentiment: Neutral
ATLANTA, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) complied with federal securities laws. On January 8, 2026, Beta Bionics announced preliminary, unaudited fourth quarter 2025 topline financial results, reporting that new patient starts, or the total number of individuals who have initiated use of the iLet Bionic Pancreas System, are expected to be below analyst estimates for the fourth quarter. Following this news, the price of the Company's stock dropped.
Read More
BBNX INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics
Published: January 23, 2026 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Beta Bionics To Contact Him Directly To Discuss Their Options
Read More
BBNX INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics
Published: January 19, 2026 by: Newsfile Corp
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Beta Bionics To Contact Him Directly To Discuss Their Options If you suffered significant losses in Beta Bionics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - January 19, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Beta Bionics, Inc. ("Beta Bionics" or the …
Read More
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics
Published: January 16, 2026 by: Newsfile Corp
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Beta Bionics To Contact Him Directly To Discuss Their Options If you suffered significant losses in Beta Bionics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - January 16, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Beta Bionics, Inc. ("Beta Bionics" or the …
Read More
Beta Bionics, Inc. (BBNX) Q3 2025 Earnings Call Transcript
Published: October 28, 2025 by: Seeking Alpha
Sentiment: Neutral
Beta Bionics, Inc. (NASDAQ:BBNX ) Q3 2025 Earnings Call October 28, 2025 4:30 PM EDT Company Participants Blake Beber - Head of Investor Relations Sean Saint - President, CEO & Director Stephen Feider - CFO, Treasurer & Secretary Conference Call Participants Michael Kratky - Leerink Partners LLC, Research Division David Roman - Goldman Sachs Group, Inc., Research Division Matthew O'Brien - Piper Sandler & Co., Research Division Stephanie Piazzola - BofA Securities, Research Division Michael Polark - Wolfe Research, LLC Frank Takkinen - Lake Street Capital Markets, LLC, Research Division Jeffrey Johnson - Robert W. Baird & Co. Incorporated, Research …
Read More
Beta Bionics: Guiding Conservative After All
Published: September 05, 2025 by: Seeking Alpha
Sentiment: Positive
Beta Bionics' iLet product is gaining traction, but management's conservative guidance has created uncertainty around future growth and competitiveness. Recent quarters showed strong revenue growth and improved guidance, but operating losses remain substantial, and operating leverage is lacking. The company's valuation has rebounded sharply, now trading at about 6 times sales, reflecting renewed optimism but also higher expectations.
Read More
Beta Bionics, Inc. (BBNX) Q2 2025 Earnings Call Transcript
Published: July 31, 2025 by: Seeking Alpha
Sentiment: Neutral
Beta Bionics, Inc. (NASDAQ:BBNX ) Q2 2025 Earnings Call July 29, 2025 4:30 PM ET Company Participants Blake Beber - Head of Investor Relations Sean T. Saint - President, CEO & Director Stephen H.
Read More
BBNX Stock May Gain From Abbott Deal to Advance iLet Integration
Published: June 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Beta Bionics collaborates with Abbott to integrate its iLet system with a dual sensor, aiming to simplify and enhance diabetes care.
Read More
Beta Bionics: Slowing Down Or Being Conservative?
Published: April 24, 2025 by: Seeking Alpha
Sentiment: Negative
Beta Bionics' iLet product offers a simplified diabetes treatment, but shares have plunged 60% since the IPO due to a non-inspiring 2025 outlook, indicating potential lost market momentum. Despite strong initial growth and a significant IPO, the company's operating losses and competitive risks warrant a cautious investment stance. The 2025 sales guidance of $80-$85 million implies no sequential growth, raising concerns about market competitiveness and potential margin pressure.
Read More
Beta Bionics to Announce Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
IRVINE, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its fourth quarter and full year 2024 financial results after the financial markets close on Tuesday, March 25, 2025. Management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to review the company's fourth quarter and full year 2024 performance.
Read More
About Beta Bionics, Inc. (BBNX)
- IPO Date 2025-01-30
- Website https://www.betabionics.com
- Industry Medical - Equipment & Services
- CEO Sean T. Saint
- Employees 352